This randomized study was designed to evaluate the efficacy and safety of IPu-infused liatermin (15mg/putamen/day) compared with placebo in subjects with symptomatic, levodopa-response Parkinson's disease. This study consisted of a 90-day evaluation period followed by implantation of the IPu delivery system and then a 6-month double-blind treatment period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
United Parkinson's Disease Rating Scale
Timed Motor Tests
Dyskinesia ratings
Diary ratings
Patient reported outcomes measures
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.